were included. In catheter-related bloodstream infection, there was no statistical significance between second-generation impregnated catheter compared with the non-impregnated ones, absolute relative risk 1,5% confidence interval 95% (3%-1%), relative risk 0,68 (confidence interval 95%, 0,40-1,15) and number needed to treat 66. In the sensitivity analysis, there was less bloodstream infection in impregnated catheters (relative risk 0,50, confidence interval 95%, 0,26-0,96). Lower colonization, absolute relative risk 9,6% (confidence interval 95%, 10% to 4%), relative risk 0,51 (confidence interval 95% from 0,38-0,85) and number needed to treat 5. Conclusion: the use of second-generation catheters was effective in reducing the catheter colonization and infection when a sensitivity analysis is performed. Future clinical trials are suggested to evaluate sepsis rates, mortality and adverse effects.
Introduction
The Central Venous Catheters (CVC) are indispensable for the treatment of critical patients both with acute and chronic illnesses. In the United
States there are more than 15 million days of CVC yearly in Intensive Care Units (ICU) (meaning 15 million total days of patients exposed to CVC in the selected population) (1) . In the United Kingdom, close to 200.000 CVC are inserted every year (2) .
CVC's are beneficial to therapy, being used for specialized diagnosis and treatments, hemodynamic monitoring, parenteral nutrition, extreme osmolarity and pH fluids delivery, chemotherapy, blood and hemocomponents infusion, hemodialysis and long term antibiotic therapy. However, there are significant risks during its utilization, among them the Catheter-Related
Bloodstream Infection (CRBSI) that is associated to the extended length-of-stay in up to three weeks, to morbidity, mortality and hospitalization costs (3) (4) .
Several procedures are performed in order to prevent the CRBSI's such as the use of a maximal sterile barrier (cap, mask, sterile gown, gloves and sterile drapes), reduction in the time for catheter insertion, cutaneous antisepsis with clorhexidine 2% in the CVC insertion site, educational programs for the health teams, and avoiding femoral vein for the insertion (5) . Additionally it has been proposed the impregnation, coating or linkage with antimicrobials to prevent the CRBSI's (5) (6) Two types of antimicrobial agents are used to coat or impregnate the CVC -antiseptics and antibiotics.
This research is focused on the second-generation CVC's impregnated in the antiseptics clorhexidine and silver sulfadiazine that have as characteristics not only the external coating but the inclusion of these antiseptics in the internal surface, the extension lines and hub (7) .
The decision to use the second-generation CVC's impregnated in clorhexidine and silver sulfadiazine is well grounded when there is a concern in expanding the prevention of CRBSI's and after the implementation of at least three basic measures to reduce infection, the training of the team that inserts and cares for the CVC, the use of maximal sterile barrier during the insertion and the cutaneous antisepsis in the insertion site of the CVC with clorhexidine at 20% (5) .
The second-generation CVC is recommended by the Centers for Disease Control and Prevention (CDC) for patients that will stay for more than five days with the device (5) and is useful in the treatment of intensive care patients, burn patients, neutropenia patients and populations with an infection rate exceeding 3,3 per 1000 catheter/day, even when adhering to the basic preventive measures (5, (8) (9) . It is indicated in patients with previous episodes of CRBSI's and with limited options for venous access (10) , or for those with a risk factor for complications of CRBSI, such as valve or endovascular graft bearers (8, 10) .
In Brazil, second-generation, clorhexidine and silver sulfadiazine-impregnated CVC's are approved for use, by the National Agency for Health Surveillance (ANVISA) through register number 10216830036 with double and triple lumen 7 Fr. x 20 cm (11) .
The evaluation of the evidence on the effectiveness of this catheter in preventing bloodstream infection prevention is still scarce and in that sense the proposal of the present research was to search for evidence to support the decision-making process for introducing this catheter in the clinical practice.
Taking into account the specificity in the use of In the case of duplicate studies, the one with more complete or recent information was included.
The degree of concordance between reviewers was measured through the Kappa coefficient (13) and the index was 0,988 with a p=<0,001, showing high concordance between the two reviewers (13) .
For the primary outcome CRBSI, were considered those patients or catheters with lab evidence of CRBSI, defined as those with isolated micro-organisms, from one or more positive blood cultures, collected separately (from peripheral blood and catheter) without any other identifiable infection source (5, 14) .
Other diagnostic criteria were considered as long as they were justified by valid sources.
The secondary outcomes were defined as follows: The clinical heterogeneity was assessed through the type of participants, interventions and outcomes of each study. The meta-analysis was performed by outcome. The statistical heterogeneity was calculated through chi-squared test with significance level set at 10% (p<0,10) (13) . The heterogeneity test was only calculated when the meta-analysis had two or more studies and then was computed the I 2 test. The heterogeneity was considered as important when I 2 was larger that 50%.
The rates of CRBSI per 1.000 catheter/day were calculated using the methods as stated in chapter 9.4.8 of Cochrane Handbook (13) . Firstly the RR was calculated by dividing the intervention group rate by the control group rate. The relative risk logarithm (log (In)) was entered in the Review Manager, 5.3.0 and the generic inverse variance was used.
Sensitivity analysis was performed for the primary outcome CRBSI and for the secondary ones as reported by the studies. Meta-analysis was done taking aside the low methodological quality studies as classified by the tool for assessing risk of bias in randomized controlled clinical trials.
The GRADE (Grading of Recommendations
Assessment, Development and Evaluation) system was used to evaluate the quality of the evidences, the size of the interventions and the total of data available about the main results of the systematic review. For the statistical analysis, the GRADEpro 3.6 program was used.
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Results
Of the 1.235 studies identified, 97 were pre- Three studies were performed in ICU's. One of them in 14 ICU's in university hospitals in France (16) , one in a medical-surgical ICU in a private hospital in Brazil (17) and one in ICU's of nine medical centers linked to USA universities (18) . One study (19) addressed the cases of patients with malignant hematological disorders in a university hospital in Heidelberg, Germany.
In regard to the number of patients in the intervention and control groups, there was equivalence, In relation to the clinical characteristics of the patients hospitalized in the E1 study (16) , they were clinical causes (control group 39%, intervention group 46%), scheduled surgeries (control group 13% and intervention group 10%), surgical trauma (control group 21% and intervention group 17%). Regarding the current antibiotic use, 58% were in the intervention group and 66% in the control group.
In the E2 study (17) , the diagnoses of patients admitted to ICU were linked to cardiac disorders (intervention group 4% and control group 10%), trauma (intervention group 5% and control group 3%), postoperative patients (intervention group 10% and control group 7%), respiratory failure patients (intervention group 39% and control group 30%).
Antibiotic therapy was being administered in 84% of the intervention group and 79% of the control group.
In study E3 (19) , patients had diagnosis of multiple myeloma (intervention group 47% and control group 42%); non-Hodgkin lymphoma (intervention group 18% and control group 15%), acute leukemia (15% in both groups). Antibiotic therapy was being administered in 6% of the intervention group and 7%
of the control group.
In the E4 (18) In the first domain results happened because the study authors did not provide enough information regarding the blinding of the participants that handled the catheter (characteristic).
In the second domain, the incomplete data about losses and exclusions were the cause of the rise of the attrition bias rates and put the studies in high bias risk. There was a 50% of uncertain bias risk linked to allocation concealment, due to the lack of details about the methodology that, even though described the studies as controlled or blind, did not specified the research design data, impeding a good evaluation of the results quality.
Related to the selective outcomes reporting domain, 75% of the studies described the results of the main outcomes. For the domain Blinding of the outcomes assessors, 75% of the studies expressed how this blinding was done. In the Randomized sequence generation, only 25% of the studies were clear regarding the way this allocation sequence generation was performed.
Only the E4 (18) study showed a low bias risk in all the assessed domains, proof of a high methodological quality. In three studies there was at least two domains classified as uncertain bias risk E1 (16) , E2 (17) , and E3 (19) and one E2 (17) with two domains in the high bias risk classification.
www.eerp.usp.br/rlae Three studies E1 (16) , E2 (17) and E4 (19) describe the colonization per 1000 catheter/day, amounting to a total of 1.189 patients. No statistical differences were found related to benefits or harmful effects between impregnated or non-impregnated catheters with a RR of 0.69 (CI 95%, 0.47-1.01).
In the sensitivity analysis for the Colonization outcome, when the E2 (17) is not considered, the heterogeneity was of I²=30% showing a low heterogeneity among studies. There was a decreased colonization in the impregnated catheters when compared with the non-impregnated ones with a RR of 0.45 (CI 95%, 0.33-0.62).
In studies E3 (19) and E4 (18) it was possible to run the meta-analysis for infection in the insertion site, with a total of 891 patients. No statistical difference was found between the impregnated and nonimpregnated CVC's with a RR of 0.97 (CI 95%, 0.72-1.30). Heterogeneity among studies was low I²=0%.
Regarding the permanence time of the catheter, the studies E1 (16) , E3 (19) e E4 (18) had that data for a total of 656 patients. There was no statistically significance for either benefit or harmful effects for the patients between the catheters, with RR of 1.05 (CI 95%, 0.68-1.62). The heterogeneity among studies was low I²=0%. The Sepsis outcome was exclusively identified in study E1 (16) , reporting a patient of the intervention group that presented a septic shock one hour after the insertion of the catheter, leading to its removal following a supposition that an allergic reaction may be happening, but in the end it was attributed to sepsis.
In relation to the Adverse Events outcome, in the E4 (18) study a total of 41 (10.7%) deaths were described, due to subjacent causes in the intervention group patients, and 43 (10.9%) deaths in the control group (pneumothorax, thrombosis, hematoma, hemothorax, allergic reaction and pulmonary embolism. One patient of the control group and two of the intervention group presented allergic nonanaphylactic reaction.
In study E1 (16) , a patient had pneumothorax in the intervention group; and nine had arterial puncture in the intervention group compared with two in the control group.
The studies do not show mortality associated to the catheter. In study E4 (18) , the decease causes were linked to subjacent causes.
The GRADE of this meta-analysis was evaluated according to the outcomes that allowed performing meta-analysis. For the CRBSI and infection at the insertion site outcomes, the meta-analysis quality www.eerp.usp.br/rlae analysis performed in three studies E1 (16) , E3 (19) and E4 (18) , showed significant reduction in CRBSI in the impregnated catheters (RR 0.50, CI 95% from 0.26-0.96). This result shows that one of the studies (17) had low methodological quality, meaning that it had Comparing these results with the meta-analysis of the present study, we can conclude that the results are similar for CRBSI per 1.000 catheter/day but they differ for the CRBSI's.
Analogous results to the ones in this research are identified in two meta-analyses in which there were no significant statistical differences between the first and second generation CVC impregnated in clorhexidine and silver sulfadiazine when compared to the non-impregnated, for CRBSI's with RR of 0.8 (CI 95%, 0.62-1.04) (21) . A meta-analysis (22) evaluated different types of impregnated catheters, among them those second-generation impregnated in clorhexidine and silver sulfadiazine, identifying CRBSI with OR 0.50 (CI 95%, 0.14-1.26). Related to this analysis focus, a meta-analysis (20) refers that the colonization of the first and second generation, clorhexidine and silver sulfadiazine In other studies, results found were alike to the ones in this research. In a meta-analysis (21) that assessed first and second-generation catheters, the RR for colonization was 0.58 (CI 95% from 0.43-0.77). In another meta-analysis (22) the colonization in the clorhexidine and silver sulfadiazine impregnated CVC's, was also decreased (OR 0.37, CI 95% from 0.17 -0.69).
Another outcome researched in this study was the time of permanence of the catheter, evaluated in three of the studies E1 (16) , E2 (17) and E3 (19) , however, it did not present differences of statistical significance, due to the small number of included studies.
Infection in the insertion site was evaluated in studies E3 (19) and E4 (18) , but no statistically significant difference was found, explained by the differences among the participants and the small number of included studies. Sepsis and mortality were not evaluated for the lack of available data in the selected studies.
The adverse effects mentioned were linked to the mechanical complications (pneumothorax, Rev. Latino-Am. Enfermagem 2016;24:e2722 hemothorax, pulmonary embolism, arterial puncture and hematoma), allergic reactions and nonanaphylactic allergic reactions. Not withstanding this fact, the allergic reactions were not described and only two studies reported those cases (16, 18) .
No studies were found that dealt with the secondgeneration CVC's used in the infant population; the selected studies were solely addressing adults.
During the selection of the studies for this research, we found studies directed to children just with firstgeneration CVC's impregnated with clorhexidine and silver sulfadiazine but these studies did not report the findings for children and adults separately.
The rest of the studies were done with catheters impregnated with Minocycline and Rifampicin, silver and heparin, encompassing randomized clinical trials and cohort observational studies.
We can thus affirm that there were no evidences allowing to evaluate the effectiveness and safety of the second-generation, clorhexidine and silver sulfadiazine impregnated catheters in the onset of sepsis, mortality, collateral effects and length-ofstay.
The present review had as limitations the insufficient number of studies that did not allow the meta-analysis for the following outcomes: sepsis, mortality and adverse effects. Only the study E4 CVC's for preventing the CRBSI (5, 8) .
Conclusions
Regarding the practice implications, the selected studies that used second-generation, clorehexidine and silver sulfadiazine impregnated CVC's evidenced benefits in the reduction of catheter colonization, In spite of the recommendations that point to the need of using second-generation, clorhexidine and silver sulfadiazine impregnated catheter, caution is required when recommending them as it was not possible to evaluate the befits in relation to sepsis, mortality and adverse effects, and also the majority of assessed population were patients of Intensive Care
Units.
For future studies, it is recommended: to include relevant outcomes such as sepsis evaluation, mortality and adverse effects, larger samples to minimize the error margin and expand the precision of the results, extended and better details on the blinding procedures,
to implement the quality of the study and bring down the bias, to describe more clearly the characterization of the participants and the measures for controlling infection adopted in-site, and evaluate the economic impact of the catheter use.
We recommend studies with infants to determine the effectiveness of second-generation, clorhexidine and silver sulfadiazine impregnated CVC's in this population, and to estimate the CRBSI that is linked to the use of such catheter, as well as colonization, sepsis, mortality, adverse effects and costs.
